Transwin Group and Bristol-Myers Squibb Collaborate on Global Clinical Trial of TST001 Combined with Opdivo(R) in Patients with Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Cancer

The collaboration includes two open, multi-center Phase I/II global clinical studies, conducted in China and the United States

Pursuant to the terms of the agreement, Transwin Group will act as the sponsor of the clinical study, and Bristol-Myers Squibb will provide Opdivo® to Transwin Group ^for conducting clinical studies related to the combination of TST001

Metastatic gastric cancer and gastroesophageal junction cancer are one of the most common cancers in the world, and new treatments that can improve patient survival are urgently needed

Dr.

Opdivo® is a ^trademark of Bristol-Myers Squibb Company

About TST001

TST001 is a high-affinity humanized monoclonal antibody targeting Claudin18.

About Chuangsheng Group

Chuangsheng Group is a clinical-stage biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production

Headquartered in Suzhou, Chuangsheng Group has successfully established a global business layout: there are drug discovery, clinical and translational research centers in Suzhou, and the headquarters of Chuangsheng Group and a production base with continuous perfusion production technology as its core technology are also under construction

For more information about Transcenta Group, please visit the company website:or LinkedIn account: Transcenta

Forward-Looking Statements

Information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made

For more information, please contact

Investor Relations: ir@transcenta.